Skip to Content

'
Alpa M. Nick, M.D., M.S.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

 

I am currently an assistant professor at the University of Texas MD Anderson Cancer Center. In addition to my clinical responsibilities, my areas of research focus on assessment of perioperative outcomes among patients undergoing minimally invasive surgery for the treatment of gynecologic malignancies, the development of novel therapies for the treatment of ovarian cancer, the development of biomarkers for the detection of ovarian cancer, and prognostic markers for those patients who undergo neoadjuvant chemotherapy for ovarian cancer. I serve as the PI or Collaborator on many novel therapeutics trials for treatment of gynecologic malignancies. 

Education & Training

N/A

Board Certifications

12/2014 American Board of Obstetrics and Gynecology

Experience/Service

Institutional Committee Activities

Member, Fellowship Admissions Subcommittee, 2010-2011
Member, Fellowship Didactic Curriculum Subcommittee, 2010

Honors and Awards

2011 Scholar-in-Training Award finalist, American Association of Cancer Research (AACR)
2009 Ovarian Cancer Research Grant, Gynecologic Cancer Foundation (GCF)/Ann Schreiber
2008 J.G. Moore Award for Best Basic Science Paper, "Therapeutic Gene Silencing in Ovarian Carcinoma: Making the Case for P130CAS", Western Association of Gynecologic Oncologists Annual Meeting,
2008 Trainee Excellence Award, M.D. Anderson Cancer Center
2006-2007 Administrative Chief Resident, Vanderbilt University Medical Center
2006 Felix Rutledge Fellowship, M. D. Anderson Cancer Center
2003 Horace E. Thompson, M.D. Award for Excellence in Obstetrics and Gynecology, Louisiana State University Health Sciences Center School of Medicine
2002 Alpha Omega Alpha, Louisiana State University Health Sciences Center School of Medicine
1997-1998 University Award for Academic Excellence in Biochemistry, Louisiana State University
1997 American Heart Association Grant for Undergraduate Research, Louisiana State University
1997 Outstanding Student in Biochemistry, Louisiana State University
1995-1996 Phi Eta Sigma Honor Society, Louisiana State University

Professional Memberships

AAGL, Cypress, CA
Member, 12/2011-present
American Association for Cancer Research
Member, 8/2007-present
American Medical Student Association
Member, 1999-2003
American Society of Clinical Oncology
Member, 7/2007-present
American Society of Plant Physiology
Member, 1997-1998
Society of Gynecologic Oncologists
Member, 7/2007-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Clark LH, Soliman PT, Odetto D, Munsell MF, Schmeler KM, Fleming N, Westin SN, Nick AM, Ramirez PT. Incidence of trocar site herniation following robotic gynecologic surgery. Gynecol Oncol 131(2):400-3, 11/2013. e-Pub 8/27/2013. PMID: 23988416.
2. Urh A, Soliman PT, Schmeler KM, Westin S, Frumovitz M, Nick AM, Fellman B, Urbauer DL, Ramirez PT. Postoperative outcomes after continent versus incontinent urinary diversion at the time of pelvic exenteration for gynecologic malignancies. Gynecol Oncol 129(3):580-585, 6/2013. PMID: 23480870.
3. Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, Huang J, Nick AM, Lopez-Berestein G, Coleman RL, Baggerly KA, Sood AK. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol 128(3):506-511, 3/2013. PMID: 23200915.
4. Schmeler KM, Wilson GL, Cain K, Munsell MF, Ramirez PT, Soliman PT, Nick AM, Frumovitz M, Coleman RL, Kroll MH, Levenback CF. Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies. Gynecol Oncol 128(2):204-208, 2/2013. PMID: 23200912.
5. Armaiz-Pena GN, Allen JK, Cruz A, Stone RI, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu, Z, English RD, Soman KV, Shazhad MM, Zigler M, et al. Src activation by B-adrenoreceptors is a key switch for tumour metastasis. Nat Commun Jan 29(4):1403, 1/2013. PMID: 23360994.
6. You J, Zhang R, Xiong C, Zhong M, Melancon M, Gupta S, Nick AM, Sood AK, Li C. Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res 72(18):4777-86, 9/15/2012. e-Pub 8/3/2012. PMCID: PMC3445780.
7. Frumovitz M, Ramirez PT, Macapinlac HA, Klopp AH, Nick AM, Ramondetta LM, Jhingran A. Anatomic location of PET-positive aortocaval nodes in patients with locally advanced cervical cancer: implications for surgical staging. Int J Gynecol Cancer 22(7):1203-7, 9/2012. PMID: 22810967.
8. Zand B, Frumovitz M, Jofre MF, Nick AM, Dos Reis R, Munsell MF, Sangi-Haghpeykar H, Levenback C, Soliman PT, Schmeler KM, Ramirez PT. Risk factors for prolonged hospitalization after gynecologic laparoscopic surgery. Gynecol Oncol 126(3):428-31, 9/2012. e-Pub 6/2/2012. PMID: 22668880.
9. Graybill WS, Frumovitz M, Nick AM, Wei C, Mena GE, Soliman PT, dos Reis R, Schmeler KM, Ramirez PT. Impact of smoking on perioperative pulmonary and upper respiratory complications after laparoscopic gynecologic surgery. Gynecol Oncol 125(3):556-60, 6/2012. e-Pub 3/17/2012. PMID: 22433464.
10. Pareja R, Nick AM, Schmeler KM, Frumovitz M, Soliman PT, Buitrago CA, Borrero M, Angel G, Reis RD, Ramirez PT. Quality of laparoscopic radical hysterectomy in developing countries: a comparison of surgical and oncologic outcomes between a comprehensive cancer center in the United States and a cancer center in Colombia. Gynecol Oncol 125(2):326-9, 5/2012. e-Pub 1/16/2012. PMID: 22261300.
11. Worley MJ, Anwandter C, Sun CC, dos Reis R, Nick AM, Frumovitz M, Soliman PT, Schmeler KM, Levenback CF, Munsell MF, Ramirez PT. Impact of surgeon volume on patient safety in laparoscopic gynecologic surgery. Gynecol Oncol 125(1):241-4, 4/2012. e-Pub 1/10/2012. PMID: 22240566.
12. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366(7):610-8, 2/16/2012. PMCID: PMC3296780.
13. Nick AM, Frumovitz MM, Soliman PT, Schmeler KM, Ramirez PT. Fertility sparing surgery for treatment of early-stage cervical cancer: Open vs. robotic radical trachelectomy. Gynecol Oncol 124(2):276-80, 2/2012. e-Pub 10/27/2011. PMID: 22035808.
14. Pecot CV, Bischoff FZ, Mayer JA, Wong KL, Pham T, Bottsford-Miller J, Stone RL, Lin YG, Jaladurgam P, Roh JW, Goodman BW, Merritt WM, Pircher TJ, Mikolajczyk SD, Nick AM, Celestino J, Eng C, Ellis LM, Deavers MT, Sood AK. A novel platform for detection of CK+ and CK- CTCs. Cancer Discov 1(7):580-586, 12/1/2011. PMCID: PMC3237635.
15. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J, Kim HS, Lee JS, Kim SM, Baggerly KA, Ram PT, Deavers MT, Coleman RL, Lopez-Berestein G, Sood AK. Silencing of p130Cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell Death. J Natl Cancer Inst 103(21):1596-612, 11/2/2011. e-Pub 9/28/2011. PMCID: PMC3206039.
16. Soliman PT, Frumovitz M, Sun CC, Dos Reis R, Schmeler KM, Nick AM, Westin SN, Brown J, Levenback CF, Ramirez PT. Radical hysterectomy: A comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology. Gynecol Oncol 123(2):333-6, 11/2011. e-Pub 8/27/2011. PMID: 21872911.
17. Hu W, Lu C, Dong HH, Huang J, Shen DY, Stone RL, Nick AM, Shahzad MM, Mora E, Jennings NB, Lee SJ, Roh JW, Matsuo K, Nishimura M, Goodman BW, Jaffe RB, Langley RR, Deavers MT, Lopez-Berestein G, Coleman RL, Sood AK. Biological roles of tumor and endothelial delta-like ligand 4 in ovarian cancer. Cancer Res 71(18):6030-9, 9/15/2011. e-Pub 7/27/2011. PMCID: PMC3174342.
18. Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN. Targeting the Notch ligand Jagged1 in both tumor cell and stroma in ovarian cancer. Clin Cancer Res 17(17):5674-85, 9/1/2011. e-Pub 7/13/2011. PMCID: PMC3166981.
19. Nick AM, Ramirez PT. The impact of robotic surgery on gynecologic oncology. J Gynecol Oncol 22(3):196-202, 9/2011. e-Pub 9/28/2011. PMCID: PMC3188719.
20. Ndofor BT, Soliman PT, Schmeler KM, Nick AM, Frumovitz M, Ramirez PT. Rate of port-site metastasis is uncommon in patients undergoing robotic surgery for gynecological malignancies. Int J Gynecol Cancer 21(5):936-40, 7/2011. PMID: 21633306.
21. Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res 17(7):1713-21, 4/1/2011. e-Pub 2/7/2011. PMCID: PMC3077122.
22. Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther 10(12):1306-14, 1/12/2011. e-Pub 12/15/2010. PMCID: PMC3047089.
23. Agarwal S, Schmeler KM, Ramirez PT, Sun CC, Nick A, Dos Reis R, Brown J, Frumovitz M. Outcomes of patients undergoing radical hysterectomy for cervical cancer of high-risk histological subtypes. Int J Gynecol Cancer 21(1):123-7, 1/2011. PMID: 21178574.
24. Nick AM, Lange J, Frumovitz M, Soliman PT, Schmeler KM, Schlumbrecht MP, dos Reis R, Ramirez PT. Rate of vaginal cuff separation following laparoscopic or robotic hysterectomy. Gynecol Oncol 120(1):47-51, 1/2011. e-Pub 9/24/2010. PMID: 20869763.
25. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 9(12):3186-99, 12/2010. e-Pub 10/1/2010. PMCID: PMC3005138.
26. Langley G, Smith W, Nick A, Rhodes H. Tramadol-induced flushing managed with aspirin premedication. J Pain Symptom Manage 40(6):7-8, 12/2010. PMID: 21145467.
27. Smith AL, Frumovitz M, Schmeler KM, dos Reis R, Nick AM, Coleman RL, Ramirez PT. Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy? Gynecol Oncol 119(2):183-6, 11/2010. e-Pub 8/12/2010. PMID: 20708227.
28. Nick AM, Schmeler KM, Frumovitz MM, Soliman PT, Spannuth WA, Burzawa JK, Coleman RL, Wei C, dos Reis R, Ramirez PT. Risk of thromboembolic disease in patients undergoing laparoscopic gynecologic surgery. Obstet Gynecol 116(4):956-61, 10/2010. PMID: 20859161.
29. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell 18(2):185-97, 8/9/2010. PMCID: PMC2923653.
30. Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, Lee SJ, Roh JW, Nick AM, Lopez-Berestein G, Sood AK. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 16(15):3910-22, 8/1/2010. e-Pub 6/10/2010. PMCID: PMC2912984.
31. Spannuth WA, Mangala LS, Stone RL, Carroll AR, Nishimura M, Shahzad MM, Lee SJ, Moreno-Smith M, Nick AM, Liu R, Jennings NB, Lin YG, Merritt WM, Coleman RL, Vivas-Mejia PE, Zhou Y, Krasnoperov V, Lopez-Berestein G, Gill PS, Sood AK. Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther 9(8):2377-88, 8/2010. e-Pub 8/3/2010. PMCID: PMC2933364.
32. Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res 16(9):2562-70, 5/1/2010. e-Pub 4/13/2010. PMID: 20388851.
33. Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, Han HD, Shahzad MM, Liu X, Bhavane R, Gu J, Fakhoury JR, Chiappini C, Lu C, Matsuo K, Godin B, Stone RL, Nick AM, Lopez-Berestein G, Sood AK, Ferrari M. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 70(9):3687-96, 5/1/2010. PMCID: PMC3202607.
34. Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, Han LY, Kamat AA, Shahzad MM, McIntyre BW, Diaz-Montero CM, Jennings NB, Lin YG, Merritt WM, DeGeest K, Vivas-Mejia PE, Lopez-Berestein G, Schaller MD, Cole SW, Lutgendorf SK. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 120(5):1515-23, 5/2010. e-Pub 4/12/2010. PMCID: PMC2860925.
35. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 9(4):985-95, 4/2010. e-Pub 4/6/2010. PMCID: PMC2852465.
36. Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 9(3):176-82, 2/2010. e-Pub 2/16/2010. PMCID: PMC3155813.
37. Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res 16(1):184-94, 1/1/2010. e-Pub 12/22/2009. PMID: 20028751.
38. Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther 8(23):2263-72, 12/2009. e-Pub 12/19/2009. PMCID: PMC3400500.
39. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 114(3):431-6, 9/2009. e-Pub 6/13/2009. PMID: 19524286.
40. Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 101(17):1193-205, 9/2009. e-Pub 7/2009. PMCID: PMC2736292.
41. Merritt WM, Danes CG, Shahzad MM, Lin YG, Kamat AA, Han LY, Spannuth WA, Nick AM, Mangala LS, Stone RL, Kim HS, Gershenson DM, Jaffe RB, Coleman RL, Chandra J, Sood AK. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther 8(16):1596-603, 8/2009. e-Pub 8/13/2009. PMID: 19738426.
42. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MM, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 15(11):3770-80, 6/1/2009. e-Pub 5/26/2009. PMCID: PMC2752981.
43. Shahzad MM, Lu C, Lee JW, Stone RL, Mitra R, Mangala LS, Lu Y, Baggerly KA, Danes CG, Nick AM, Halder J, Kim HS, Vivas-Mejia P, Landen CN, Lopez-Berestein G, Coleman RL, Sood AK. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther 8(11):1027-34, 6/2009. e-Pub 6/24/2009. PMCID: PMC2748749.
44. Armaiz-Pena GN, Mangala LS, Spannuth WA, Lin YG, Jennings NB, Nick AM, Langley RR, Schmandt R, Lutgendorf SK, Cole SW, Sood AK. Estrous cycle modulates ovarian carcinoma growth. Clin Cancer Res 15(9):2971-8, 5/1/2009. e-Pub 4/21/2009. PMCID: PMC2743312.
45. Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, Nick AM, Stone RL, Lu C, Lutgendorf SK, Cole SW, Lokshin AE, Sood AK. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 15(8):2695-702, 4/15/2009. e-Pub 4/7/2009. PMCID: PMC2746852.
46. Spannuth WA, Nick AM, Jennings NB, Armaiz-Pena GN, Mangala LS, Danes CG, Lin YG, Merritt WM, Thaker PH, Kamat AA, Han LY, Tonra JR, Coleman RL, Ellis LM, Sood AK. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 124(5):1045-53, 3/1/2009. PMCID: PMC2668132.
47. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359(25):2641-50, 12/18/2008. PMCID: PMC2710981.
48. Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 10(11):1259-67, 11/2008. PMCID: PMC2570602.
49. Lin YG, Immaneni A, Merritt WM, Mangala LS, Kim SW, Shahzad MM, Tsang YT, Armaiz-Pena GN, Lu C, Kamat AA, Han LY, Spannuth WA, Nick AM, Landen CN, Wong KK, Gray MJ, Coleman RL, Bodurka DC, Brinkley WR, Sood AK. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res 14(17):5437-46, 9/1/2008. PMCID: PMC2766914.
50. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, Vivas-Mejia PE, Deavers MT, Coleman RL, Lopez-Berestein G, Mehta K, Sood AK. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 68(14):5849-58, 7/15/2008. PMCID: PMC2547344.
51. Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, Nick AM, Jennings N, Kinch MS, Bar-Eli M, Sood AK. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 7(7):1098-103, 7/2008. e-Pub 4/19/2008. PMCID: PMC2705979.
52. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G, Sood AK. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 67(22):10976-83, 11/15/2007. PMID: 18006843.
53. Nick AM, Bruner JP, Moses R, Yang EY, Scott TA. Second-trimester intra-abdominal bowel dilation in fetuses with gastroschisis predicts neonatal bowel atresia. Ultrasound Obstet Gynecol 28(6):821-5, 11/2006. PMID: 17029299.
54. Milam MR, Pollock JW, Nick AM, Scott T, Jones HW. The effect of hormonal contraception on the adequacy of colposcopic examination of the cervix. Am J Obstet Gynecol 192(5):1368-9, 5/2005. PMID: 15902111.
55. Manchandia AM, Banks SW, Gossett DR, Bellaire B, Lucus MC, Millhollon, EP. The influence of alpha-amanitin on the NaCl-induced up-regulation of antioxidant enzyme activity in cotton callus tissue. Free Radical Research(30):429-438, 1999. PMID: 10400455.

Invited Articles

1. Ramirez P, Nick A, Frumovitz M, Schmeler K. Venous Thromboembolic Events in Minimally Invasive Gynecologic Surgery. The Journal of Minimally Invasive Gynecology 20(6):766-769, 11/2013.
2. Nick AM, Sood AK. The ROC n’ Role of the Multiplex Assay for Early Detection of Ovarian Cancer. Clinical Cancer Research 14(4):1065-72, 2008.

Abstracts

1. Clark LH, Soliman PT, Odetto D, Munsell ME, Schmeler KM, Fleming N, Westin SN, Nick Am, Ramirez PT. Incidence of trocar site herniation following robotic gynecologic surgery. Gynecol Oncol, 8/2013. PMID: 23988416.
2. Hu W, Ivan C, Bottsford-Miller J, Zand B, Dalton H, Nick A, Lopez-Berestein G, Coleman R, Bagglerly K, Sood A. Comprehensive epigenetic analysis of Notch pathway in high-grade serous ovarian cancer. Gynecologic Oncology 130(1):e115, 7/2013.
3. Zand B, Ivan C, Pecot C, Rupaimoole R, Dalton H, Bottsford-Miller J, Hu W, Nick A, Sood A. Deception of suppression: Unexpected effects of tristetraprolin in ovarian cancer. Gynecologic Oncology 130(1):e-128, 7/2013.
4. Watkins J, Thaker P, Nick A, Ramondetta L, Kumar S, Matsuo K, Lutgendorf S, Ramirez P, Sood A. Improved outcomes with beta blocker use in epithelial ovarian cancer patients. Gynecologic Oncology 130(1):e31, 7/2013.
5. Soliman P, Sun C, Westin S, Fleming N, Schmeler K, Nick A, Ramirez P. Improvement in quality of life after robotic surgery results in patient satisfaction. Gynecologic Oncology 130(1):e147-e148, 7/2013.
6. Zand B, Ivan C, Pecot C, Rupaimoole R, Dalton H, Bottsford-Miller J, Hu W, Nick A, Sood A. Separating the good, the bad, and the ugly. Gynecologic Oncology 130(1):e5-e6, 7/2013.
7. Dalton H, Ivan C, Pecot C, Rupaimoole R, Zand B, Bottsford-Miller J, Hu W, Nick A, Coleman R, Sood A. The Eph Family: Not playing nice in uterine cancer. Gynecologic Oncology 130(1):e6, 7/2013.
8. Carroll A, Ramirez P, Westin S, Soliman P, Munsell M, Nick A, Schmeler K, Frumovitz M, Klopp A, Fleming N. Uterine adenosarcoma: A closer look at a rare disease. Gynecologic Oncology 130(1):e152, 7/2013.
9. Bandyopdhyay J, Munsell M, Schmeler K, Nick A, Westin S, Fleming N, Ramirez P, Soliman P. Risk Factors Associated with Conversion to Laparotomy in Patients Undergoing Robotic Surgery. The Journal of Minimally Invasive Gynecology 19(6 Supplement):Page S89, 11/2012.
10. Graybill, WS, Frumovitz M, Nick AM, Wei C, Mena GE, Soliman P T, dos Reis R, Schmeler KM, Ramirez PT. Impact of smoking on perioperative pulmonary and upper respiratory complications after laparoscopic gynecologic surgery. Gynecologic Oncology 125(3):556-560, 6/2012.
11. Worley Jr. M.J, Anwandter C, Sun CC, dos Reis R, Nick AM, Frumovitz M, Soliman PT, Schmeler KM, Levenback C, Munsell MF, Ramirez, PT. Impact of surgeon volume on patient safety in laparoscopic gynecologic surgery. Gynecologic Oncology 125(Supplement 1):241-244, 4/2012.
12. Nick A, Mora E, Pecot C, Bottsford-Miller J, Stone R, Hu W, Urbauer D, Lopez-Berenstein G, Jackson D, Sood A. Discovery of an alternate erythropoietin receptor: The Eph connection, Gynecologic Oncology. Gynecologic Oncology 125(Supplement 1):S108, 3/2012.
13. Hu W, Ivan C, Bottsford-Miller J, Zand B, Pecot C, Nick A, Stone R, Coleman R, Baggerly K, Sood A. Integrated analysis of Notch pathway in high grade serous ovarian cancer. Gynecologic Oncology 125(Supplement 1):S7-S8, 3/2012.
14. Zand B, Bottsford-Miller J, Nick A, Hu W, Stone R, De Geest K, Lutgendorf A, Sood A. Metabolism gone awry: How ovarian cancer's metabolism differs from the normal ovary. Gynecologic Oncology 125(Supplement 1):S131, 3/2012.
15. Schmeler K, Langley G, Cain K, Munsell M, Ramirez P, Soliman P, Nick A, Frumovitz , Garcia E, Levenback C. Reduction in venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies. Gynecologic Oncology 125(Supplement 1):S20-S21, 3/2012.
16. Iglesias D, Munsell M, Frumovitz M, Westin S, Nick A, Schmeler K, Ramirez P, Soliman P. Successful incorporation of robotic surgery into gynecologic oncology fellowship training. Gynecologic Oncology 125(Supplement 1):S125, 3/2012.
17. Stone R, Nick A, Bottsford-Miller J, King E, Matsuo K,L utgendorf S, McNeish I, Afshar-Kharghan V, Sood A. Unraveling the century-old mystery of paraneoplastic thrombocytosis in ovarian cancer. Gynecologic Oncology 125(Supplement 1):S13, 3/2012.
18. Bottsford-Miller J, Stone R, Nick A, Zand B, Pecot C, Ivan C, Hu W, Afshar-Khargan V, Sood A. Fuel on the Fire: Contribution of Thrombocytosis to Ovarian Cancer Resistance to Taxane-Based Chemotherapy. Gynecologic Oncology 125(2):S191, 2012.
19. Pecot C, Bischoff F, Lin Y, Jaladurgam P, Merritt W.M., Pircher T.J., Mikolajczyk S, Mayer JA, Wong K, Pham T, Bottsford-Miller J, Stone R, Celestino J, Nick A, Eng C. Sood A. Clinical relevance of cytokeratin-negative circulating tumor cells. Journal of Clinical Oncology, 2011 ASCO Annual Meeting Abstracts 29(No 15_suppl):e21101, 5/2011.
20. Hu W, Lu C, Stone R, Bottsford-Miller J, Nick A, Shahzad M, Matsuo K, Coleman R, Sood A. Biologic roles of tumor and endothelial delta-like ligand 4 in ovarian cancer. Gynecologic Oncology 120(Supplement 1):S35-36, 3/2011.
21. Nick A, Stone R, Bottsford-Miller J, Spannuth W, Jennings N, Bagri, Coleman R, Sood A. Neuropilin-1 blockade in the tumor microenvironment reduces tumor growth. Gynecologic Oncology 120(1, Supplement 1):s51-52, 3/2011.
22. Soliman P, Langley G, dos Reis R, Frumovitz M, Schmeler K, Nick A, Ramirez P. Postoperative analgesic and antiemetic requirements after minimally invasive surgery for early cervical cancer: Is the robot better?. Gynecologic Oncology 120(1, Supplement 1):s128, 3/2011.
23. Zand B, Nick A, Sangi-Haghpeykar H, Frumovitz M, Soliman P, Schmeler K, Ramirez P. Predictive risk factors for prolonged hospilizations after gynecologic laparoscopic surgery. Gynecologic Oncology 120(1, Supplement 1):s130, 3/2011.
24. Nick A, Stone R, Soliman P, Sood A, Gershenson D, Coleman R, Ramirez P. Pressure to respond: Hypertension predicts clinical benefit from bevacizumab in recurrent ovarian cancer. Gynecologic Oncology 120(1 Supplement 1):s36-37, 3/2011.
25. Namaky D, Ramirez P, Munsell M, Nick A, Gershenson D, Brown J. Secondary cytoreductive surgery: A key tool in the management of recurrent ovarian sex cord-stromal tumors. Gynecologic Oncology 120(1 Supplement 1):s40, 3/2011.
26. Nick A, Stone R, Bottsford-Miller, Ramirez P, Tung C, Armaiz-Pena G, Fleix E, Sood A. Stop and smell the volatile organic compounds: A novel breath-based bioassay for detection of ovarian cancer. Gynecologic Oncology 120(1 Supplement 1):S54-55, 3/2011.
27. Shahzad M, Arevalo J, Stone R, Armair-Pena G, Bottsford-Miller J, Nick A, Lutgendorf S, Lopez-Berenstein G, Cole S, Sood A. Stress and the metastatic switch in epithelial ovarian carcinoma. Gynecologic Oncology 120(1, Supplement 1):s55, 3/2011.
28. Bottsford-Miller J, Lutgendorf S, Pecot C, Stone R, Nick A, Matsuo K, King E, Ring K, De Geest K, Sood A. True blood: Platelets as a biomarker of ovarian cancer recurrence. Gynecologic Oncology 120(1, Supplement 1):S57-S58, 3/2011.
29. Stone R, Nick A, Landen C Jr, Matsuo K, King E, Carroll A, Spannuth W, Shahzad M, Gershenson D, Sood A. Bad blood: The role of platelets in ovarian carcinoma. Gynecol Oncol 116:S17 (#39), 2010.
30. Hu W, Lu C, Stone R, Bottsford-Miller J, Nick A, Shahzad M, Matsuo K, Coleman R, Sood A. Biologic roles of tumor and endothelial delta-like ligand 4 in ovarian cancer. Gynecologic Oncology 120:S35-S51, 2010.
31. Carroll A, Armaiz Pena G, Coleman R, Kim S, Lopez-Berestein G, Mangala S, Nick A, Sood A, Spannuth W, Stone R. Breaking scaffolds: Targeting pazillin in ovarian cancer. Gynecol Oncol 116:S111 (#280), 2010.
32. Lin Y, Stone R, Merritt W, Kamat A, Nick A, Spannuth W, Carroll A, Langley R, Coleman R, Sood A. Dual metronomic chemotherapy results in potent antiangiogenic effects in ovarian carcinoma. Gynecol Oncol 116:S152 (#395), 2010.
33. Landen C Jr, Goodman B, Han H, Nick A, Stone R, Jennings N, Alvarez R, Coleman R, Lopez-Berestein G, Sood A. Dual thereat: Targeting the notch ligand Jagged 1 in both tumor and stroma in ovarian cancer. Gynecol Oncol 116:S106 (#270), 2010.
34. Spannuth WA, Frumovitz M, Nick A, Mena GE, Soliman PT, dos Reis R, Schmeler KM, Ramirez PT. Impact of Smoking on Perioperative pulmonary complications in laparoscopic surgery. J Minimally Invasive Gynecology 17(6):S157, 2010.
35. Worley, Jr. MJ, Anwandter C, Sun CC, dos Reis R, Nick AM, Frumovitz M, Coleman RL, Soliman PT, Schmeler KM, Ramirz PT. Impact of surgeon volume on patient outcome in gynecologic laparoscopy. J Minimally Invasive Gynecology 17(6):S56, 2010.
36. Stone R, Lee J, Nam E, Nick A, Shahzad M, Mao S, Gooya J, Jackson D, Coleman R, Sood A. Improving delivery of cytotoxic payload to uterine cancer. Gynecol Oncol 116:S160 (#418), 2010.
37. Nick A, Stone R, Soliman P, Sood A, Gershenson D, Coleman R, Ramirez P. Pressure to respond: Hypertension predicts clinical benefit from bevacizumab in recurrent ovarian cancer. Gynecologic Oncology 120:S37-S37, 2010.
38. Sood A, Bornmann W, Coleman R, Fernandez A, Hennessy B, Lin Y, Lopez-Berestein G, Nick A, Stone R, Vivas-Mejia P. Re-engineering imatinib to make it safer and more effective. Gynecol Oncol 116:S111 (#281), 2010.
39. Nick A, Schmeler K, Frumovitz M, Soliman P, Spannuth W, Burzawa J dos Reis R, Ramirez P. Risk of thromboembolic disease in patients undergoing laparoscopic gynecologic surgery. Gynecol Oncol 116:S148 (#383), 2010.
40. Spannuth W, Kumar S, Masood R, Nick A, Lin Y, Merritt W, Coleman R, Tice D, Gill P, Sood A. Therapeutic targeting of EphB4 with a novel monoclonal antibody. Gynecol Oncol 116:S137 (#352), 2010.
41. Moreno-Smith M, Armaiz-Pena G, Allen J, Nick AM, Stone RL, Shahzad M, Lee JW, Lu C, Schmandt R, Sood AK. Dopamine blocks stress-mediated tumor growth in ovarian carcinoma. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (#3190), 2009.
42. Shahzad M, Lu C, Lee JW, Danes C, Mangala L, Halder J, Nick AM, Stone RL, Kim H, Nam E, Mora E, Landen C, Coleman RL, Lopez-Berestein G, Sood AK. Dual targeting of EphA2 and FAK in ovarian carcinoma. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (#5297), 2009.
43. Stone RL, Nick AM, Spannuth WA, Bonome T, Lutgendorf S, DeGeest K, Merritt W, Lin YG, Gershenson DM, Coleman RL, Birrer MJ, Sood AK. Focal adhesion kinase is a new focus for antiangiognesis therapy in ovarian cancer. Gynecol Oncol 112(2):S30, 2009.
44. Lin YG, Merritt W, Armaiz-Pena G, Lu C, Jennings N, Han L, Kamat A, Nick AM, Stone RL, Spannuth WA, Deavers MT, Urbauer D, Bender DP, De Geest K, Lutgendorf S, Sood AK. Functional expression of 2 adrenergic receptors on human ovarian tumors portend worse clinical outcome. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (#2506), 2009.
45. Sood AK, Mangala LS, Han H, Lu C, Ali-Fehmi R, Stone R, Munkarah A, Spannuth W, Nick AM, Lee J, Shahzad M, Guven E, Coleman RL, Denkbas E, Birrer MJ, Lopez-Berestein G. In vivo angiogenic gene silencing using chitosan nanoparticles in ovarian carcinoma. Gynecol Oncol 112(2):S122, 2009.
46. Merritt WM, Hwang J, Lin YG, Spannuth WA, Nick AM, Stone R, Landen CN, Kamat AA, Coffman K, Bruckheimer E, Gershenson DM, Coleman RL, Sood AK. Inhibition of EphA2 activity demonstrates significant antiangiogenic and antitumor effects in endometrial carcinoma. Gynecol Oncol 112(2):S77, 2009.
47. Landen CN, Goodman B, Nick AM, Armaiz-Pena G, Stone RL, Danes C, Shahzad M, Jennings N, Markman M, Gershensen DM, Cooper L, Bast R, Coleman CL, Sood AK. Isolation of potential ovarian tumor initiating cells by aldehyde dehydrogenase expression. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (#180), 2009.
48. 29. Landen CN, Goodman BW, Nick AM, Armaiz-Pena G, Danes CG, Stone RL, Shahzad M, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Sood AK. Markers for discovering stemness in ovarian cancer. Gynecol Oncol 112(2):S136, 2009.
49. Lee JW, Han HD, Shahzad M, Kim SW, Mangala L, Nick AM, LuC, Schmandt R, Kim H, Mao S, Fazenbaker C, Jackson D, Landen C, Coleman RL, Sood AK. Molecularly targeted chemotherapy using a novel EphA2 immunoconjugate in ovarian carcinoma. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (#3683), 2009.
50. Lin YG, Merritt WM, Spannuth WA, Nick AM, Stone RL, Tsinberg P, Coleman RL, Birrer MJ, Bischoff F, Sood AK. Rare circulating tumor cells can be reliably and efficiently detected using a novel microfluidics and micro-electromechanical systems (MEMS)-base rare cell recovery platform: Preclinical and clinical data. Gynecol Oncol 112(2):S117, 2009.
51. Lee JW, Shahzad M, Lin YG, Armaiz-Pena G, Mangala L, Han HD, Kim H, Nam E, Jennings N, Halder J, Nick AM, Stone RL, Lu C, Lutegendorf S, Cole SW, Loskin AE, Sood AK. Surgical stress promotes tumor growth in ovarian carcinoma. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (#3181), 2009.
52. Landen CN, Goodman B, Nick AM, Armaiz-Pena G, Stone RL, Danes C, Shahzad M, Jennings N, Markman M, Gershensen DM, Cooper L, Bast R, Coleman CL, Sood AK. Targeted gene silencing using RGD peptide labeled chitosan nanoparticles. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (#631), 2009.
53. Nick AM, Spannuth WA, Landen CN, Kim H, Kamat A, Lin YG, Merritt W, Stone RL, Mangala L, Armaiz-Pena G, Deavers M, Lopez-Berestein G, Birrer M, Coleman RL, Sood AK. Targeting p130cas in ovarian carcinoma. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (#4657), 2009.
54. Stone RL, Nick AM, Spannuth WA, Bonome T, Lutgendorf S, De Geest K, Merritt W, Lin YG, Gershenson DM, Coleman RL, Birrer MJ, Sood AK. The clinical and biological significance of focal adhesion kinase activation in ovarian carcinoma. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research (#3636), 2009.
55. Spannuth WA, Lin YG, Merritt WM, Nick AM, Stone RL, Mangala SL, Armaiz-Pena G, Landen CN, Grasso L, Phillips M, Coleman RL, Sood AK. Therapeutic efficacy of folate receptor  blockade with MORAb-003 in ovarian cancer. Gynecol Oncol 112(2):S159, 2009.
56. Nick AM, Spannuth WA, Landen CN, Jr., Kamat AA, Han LZ, Lin YG, Merritt WM, Jennings NB, Kim S, Mangala LS, Deavers M, Coleman R, Sood AK. Therapeutic Gene Silencing in Ovarian Carcinoma: Making the Case for p130cas. Gynecol Oncol 112(2):S122, 2009.

Book Chapters

1. Nick AM, Coleman RL. Gynecological Cancers: Ovarian Cancer: Neoadjuvant, Adjuvant and Surgical Issues. In: Cancer Consult, Expertise for Clinical Practice. In Press.
2. Nick AM, Coleman RL, Sood AK. Molecular therapeutics in ovarian carcinoma. In: Ovarian Cancer: State of the Art. Remedica Medical Education and Publishing Limited: London, UK, 109-160, 2009.

Grant & Contract Support

Title: A Novel Breath-based Bioassay for the Detection of Ovarian Cancer
Funding Source: UTMDACC SPORE in Ovarian Cancer
Role: Principal Investigator
Duration: 10/5/2011 - 8/31/2013

Last updated: 6/27/2014